Table of Contents Table of Contents
Previous Page  24 / 62 Next Page
Information
Show Menu
Previous Page 24 / 62 Next Page
Page Background

First

Biomarker

(DLL3)-directed

Therapy in SCLC:

Rova-T

EAP

1Q-2018